🎉 M&A multiples are live!
Check it out!

Sangamo Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Sangamo Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Sangamo Therapeutics Overview

About Sangamo Therapeutics

Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington’s Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.


Founded

1995

HQ

United States of America
Employees

183

Website

sangamo.com

Financials

LTM Revenue $61.1M

LTM EBITDA -$65.9M

EV

$157M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Sangamo Therapeutics Financials

Sangamo Therapeutics has a last 12-month revenue of $61.1M and a last 12-month EBITDA of -$65.9M.

In the most recent fiscal year, Sangamo Therapeutics achieved revenue of $57.8M and an EBITDA of -$89.1M.

Sangamo Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Sangamo Therapeutics valuation multiples based on analyst estimates

Sangamo Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $176M $57.8M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$96.8M -$89.1M XXX XXX XXX
EBITDA Margin -55% -154% XXX XXX XXX
Net Profit -$192M -$258M XXX XXX XXX
Net Margin -109% -446% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Sangamo Therapeutics Stock Performance

As of April 15, 2025, Sangamo Therapeutics's stock price is $1.

Sangamo Therapeutics has current market cap of $169M, and EV of $157M.

See Sangamo Therapeutics trading valuation data

Sangamo Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$157M $169M XXX XXX XXX XXX $-0.43

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Sangamo Therapeutics Valuation Multiples

As of April 15, 2025, Sangamo Therapeutics has market cap of $169M and EV of $157M.

Sangamo Therapeutics's trades at 2.6x LTM EV/Revenue multiple, and -2.4x LTM EBITDA.

Analysts estimate Sangamo Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Sangamo Therapeutics and 10K+ public comps

Sangamo Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $157M XXX XXX XXX
EV/Revenue 2.7x XXX XXX XXX
EV/EBITDA -1.8x XXX XXX XXX
P/E -1.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -2.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Sangamo Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Sangamo Therapeutics Valuation Multiples

Sangamo Therapeutics's NTM/LTM revenue growth is 6%

Sangamo Therapeutics's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.9M for the same period.

Over next 12 months, Sangamo Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Sangamo Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Sangamo Therapeutics and other 10K+ public comps

Sangamo Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -67% XXX XXX XXX XXX
EBITDA Margin -154% XXX XXX XXX XXX
EBITDA Growth -8% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -148% XXX XXX XXX XXX
Revenue per Employee $0.3M XXX XXX XXX XXX
Opex per Employee $0.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 77% XXX XXX XXX XXX
R&D Expenses to Revenue 193% XXX XXX XXX XXX
Opex to Revenue 270% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Sangamo Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Genomics & Personalized Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Sangamo Therapeutics M&A and Investment Activity

Sangamo Therapeutics acquired  XXX companies to date.

Last acquisition by Sangamo Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Sangamo Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Sangamo Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Sangamo Therapeutics

When was Sangamo Therapeutics founded? Sangamo Therapeutics was founded in 1995.
Where is Sangamo Therapeutics headquartered? Sangamo Therapeutics is headquartered in United States of America.
How many employees does Sangamo Therapeutics have? As of today, Sangamo Therapeutics has 183 employees.
Who is the CEO of Sangamo Therapeutics? Sangamo Therapeutics's CEO is Dr. Alexander Donald Macrae, M.B.,PhD.
Is Sangamo Therapeutics publicy listed? Yes, Sangamo Therapeutics is a public company listed on NAS.
What is the stock symbol of Sangamo Therapeutics? Sangamo Therapeutics trades under SGMO ticker.
When did Sangamo Therapeutics go public? Sangamo Therapeutics went public in 2000.
Who are competitors of Sangamo Therapeutics? Similar companies to Sangamo Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Sangamo Therapeutics? Sangamo Therapeutics's current market cap is $169M
What is the current revenue of Sangamo Therapeutics? Sangamo Therapeutics's last 12-month revenue is $61.1M.
What is the current EBITDA of Sangamo Therapeutics? Sangamo Therapeutics's last 12-month EBITDA is -$65.9M.
What is the current EV/Revenue multiple of Sangamo Therapeutics? Current revenue multiple of Sangamo Therapeutics is 2.6x.
What is the current EV/EBITDA multiple of Sangamo Therapeutics? Current EBITDA multiple of Sangamo Therapeutics is -2.4x.
What is the current revenue growth of Sangamo Therapeutics? Sangamo Therapeutics revenue growth between 2023 and 2024 was -67%.
Is Sangamo Therapeutics profitable? Yes, Sangamo Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.